EFFECT OF COGNITIVE BEHAVIORAL THERAPY ON DEPRESSION AND QUALITY OF LIFE IN PATIENTS WITH POST COVID-19

Last updated: August 5, 2023
Sponsor: Cairo University
Overall Status: Active - Enrolling

Phase

N/A

Condition

Depression

Covid-19

Treatment

rehacom

Clinical Study ID

NCT05981872
Rehacom on post covid
  • Ages 30-60
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The goal of this clinical trial is to test the effect of Rehacom on depression and Quality of life in post covid -19 patients. The main question it aims to answer is:

• Is a cognitive rehabilitation therapy will improve depression and quality of life in patients with post COVID-19? Researchers will compare Rehacom with exercise therapy to see if rehacom can improve depression and quality of life in patients with post COVID-19 neuropsychological problems.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • All patients will be selected according to following criteria:
  1. Patients from both genders (male and female).
  2. The age of participants ranged from 30 to 45 years .
  3. The patients had score more than 24 according to Mini mental state examination (MMSE).
  4. Patient muscle power not less than grade 3 .
  5. Patients are ambulant.
  6. Patients with confirmation of previous covid19 infection PCR TEST.
  7. Participants were required to live in Egypt during the pre-covid and COVID-19pandemic.
  8. Patients meeting the guide line of world health organization (WHO) oflong/post-covid 19 syndromes.
  9. Patients are "long-haulers" those who history of probable or confirmed SARS-CoV-2infection; usually within three months from the onset of COVID-19, and last morethan two months

Exclusion

Exclusion Criteria:

  • The patients will be excluded if they have any of the following:
  1. Patient previously diagnosed with depression and currently taking medication.
  2. patient had prior cognitive impairment.
  3. Illiterate patients.
  4. patient had experienced another major stressful event (e.g., divorce,bereavement) in the past year.
  5. Checking comorbidities (sum of hypertension, diabetes, arrhythmia, myocardialinfarction, Chronic Obstructive Pulmonary Disease/Asthma.
  6. Mild cognitive impairment, dementia, other neurodegenerative diseases, stroke,depression,
  7. Osteoarthritis , low back pain and prevalence of polypharmacy (5 or more drugs)at admission.

Study Design

Total Participants: 36
Treatment Group(s): 1
Primary Treatment: rehacom
Phase:
Study Start date:
May 04, 2023
Estimated Completion Date:
January 31, 2024

Study Description

Purpose of the study:

  • To investigate the effect of cognitive rehabilitation therapy on depression in post COVID-19 patients.

  • To investigate the effect of cognitive rehabilitation therapy on quality of life in post COVID-19 patients.

Significance of the study:

•There is growing evidence that individuals with COVID-19 disease can develop a range of neurological complications including cognitive and neuropsychiatric symptoms . Cognitive rehabilitation essential in improving quality of life with Introduction of new neuropsychological rehabilitation tools based on the latest developments in computer sciences.

This study aims to investigate the RehaCom as a cognitive rehabilitation program on depression and quality of life in patients suffer from post COVID-19 neuropsychological problems.

Connect with a study center

  • Faculty of physical therapy .Cairo university

    Cairo, 4240101
    Egypt

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.